A Startup Says It Grew Human Sperm in a Lab — and Used It to Make Embryos

A biotech startup called Paterna Biosciences has announced a scientific milestone that could reshape the future of fertility treatment: the company says it has successfully grown human sperm in a laboratory and used that lab-grown sperm to create embryos.

According to Paterna, researchers have determined the set of instructions needed to turn sperm-making stem cells into what the company describes as normal, mature sperm. If independently verified, this achievement would represent a major breakthrough in reproductive medicine, potentially offering new hope to millions of men who face infertility due to conditions that prevent natural sperm production.

The implications are enormous. Male infertility accounts for roughly half of all infertility cases, and current treatment options are limited. For men with conditions like azoospermia — the absence of sperm in semen — the options today are often restricted to donor sperm or adoption. Lab-grown sperm could, in theory, allow these men to have biological children.

But the announcement also raises significant ethical and regulatory questions. The creation of embryos using lab-grown sperm enters territory that many bioethicists have long flagged as needing careful oversight. Questions about the long-term health of children conceived through such methods, the potential for misuse of the technology, and the regulatory frameworks needed to govern it are all unresolved.

Paterna's claims have not yet been published in a peer-reviewed journal, which means the scientific community will need to independently validate the results before they can be considered confirmed. Several fertility researchers have expressed cautious optimism while emphasizing the need for rigorous review.

What This Means For You: If you or someone you know is struggling with male infertility, this research could eventually open doors that are currently closed. But the keyword is eventually — this technology is years away from clinical application and will face extensive regulatory scrutiny before it's available to patients. For now, it's a promising development worth watching, not a treatment option available today.